Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY2940680 in Japanese Patients with Advanced Solid Tumors
jRCT2080222179Phase 1
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taladegib in Nonhematologic neoplasms and solid tumor, sponsored by Eli Lilly and Company.
02
Drugs
taladegib
03
Conditions
Nonhematologic neoplasmssolid tumor
Beyond the preview
Go deeper on jRCT2080222179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222179.